Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cleveland BioLabs has reported encouraging results of a study that demonstrated Protectan CBLB502's ability to reduce the side effects of a chemotherapeutic drug, cisplatinum, broadly used for treatment of many types of cancer.
Subscribe to our email newsletter
In the study, CBLB502 was injected 30 minutes before cisplatinum at a dose of 1mcg/mouse (0.04mg/kg, which is less than 1% of maximal tolerable dose). Cisplatinum was injected either at maximal tolerable dose or at double maximal tolerable dose. In mice that received the maximal tolerable dose of cisplatinum, CBLB502-pretreated animals showed neither weight loss nor behavioral signs of morbidity, both of which were seen in all of the control group mice.
Cleveland BioLabs plans to initiate a Phase I/II study in the first half of 2008 for CBLB502 in head and neck cancer patients for reduction of side effects of radiation and chemotherapy, such as mucositis, which can be a treatment-limiting factor.